• Corpus ID: 30490902

[Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)].

  title={[Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)].},
  author={Luc P. Balant and A. Gorgia and Antoine Marmy and Jean-Marie Tschopp},
  volume={1 4},
Tolamolol is subject to first-pass metabolism and is eliminated from the body almost entirely by biotransformation. Its major metabolite in plasma (4-hydroxy-tolamolol) is biologically active and may contribute to the pharmacological effect of the drug. The effect of renal failure on the behaviour of the parent compound and of its metabolite was studied by comparing their kinetics in normal volunteers and in patients with severe renal insufficiency. Tolamolol was given orally to all subjects at… 
5 Citations
Differential consequences of renal failure on the pharmacokinetics of Oxprenolol and its main metabolite
Administration of Oxprenolol does not require dosage adjustement in patients with severe renal failure, and this dose did not result in any major difference in cardiac effect between patients and healthy subjects.
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup
Atenolol and sotalol were assessed as dialyzable in patients with kidney impairment, and the workgroup suggests ECTR in patients severely poisoned with these drugs when aforementioned indications are present, whereas other BAAs were considered Dialyzable, clinical data were too limited to develop recommendations.
Les répercussions de l’insuffisance rénale chronique sur le transport des médicaments
The results show modulations in the expression and activity of hepatic influx and efflux drug transporters that could lead to decreases in the hepatic metabolism and biliary excretion of drugs.
Current Understanding of Drug Disposition in Kidney Disease
This review summarizes recent preclinical and clinical studies and presents the current understanding of the effect of CKD on drug absorption, distribution, metabolism, and excretion.
A Toxicological Review of Beta-Adrenergic Blockers
Eighteen beta-adrenergic blockers have been reviewed and the available literature pertaining to their potential carcinogenicity, mutagenicity, and teratogenicity has been summarized and compared.